Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30096606 | 1.00 | CA12 (0.40) | CA12CA9ALOX15HSD17B10JAK2 | |
| SCHEMBL30340726 | 0.94 | CA12 (0.40) | CA12CA9ALOX15HSD17B10JAK2 | |
| SCHEMBL17949690 | 0.94 | CA12 (0.40) | CA12CA9ALOX15HSD17B10JAK2 | |
| SCHEMBL23044043 | 0.78 | KDM4E (0.41) | METAP2MAPK8MAPK9MAPK10PLK4 | |
| SCHEMBL21340386 | 0.76 | ACVR1 (0.39) | GAACDK1CDK2PDGFRALTK | |
| SCHEMBL20854469 | 0.75 | METAP2 (0.53) | CA12CA9ALOX15HSD17B10JAK2 | |
| Dihydrophenanthridine SCHEMBL29791568 | 0.73 | CA12 (0.56) | CA12CA9ALOX15HSD17B10JAK2 | |
| Dihydrophenanthridine SCHEMBL2087461 | 0.73 | CA12 (0.56) | CA12CA9ALOX15HSD17B10JAK2 | |
| SCHEMBL24976109 | 0.73 | ALDH1A1 (0.37) | HSD17B10GAACDK1CDK2MAPK8 | |
| SCHEMBL727511 | 0.73 | ALDH1A1 (0.37) | HSD17B10GAACDK1CDK2MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096366-A1 | CONJUGATES FOR DELIVERY ACROSS THE BLOOD BRAIN BARRIER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-05-08 | — | — | WO | claimed |
| US-20250228954-A1 | Designing Antisense Oligonucleotide Delivery Peptides by Interpretable Machine Learning | SAREPTA THERAPEUTICS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250161469-A1 | TRIMERIC PEPTIDES FOR ANTISENSE DELIVERY | SAREPTA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2025096366-A1 | CONJUGATES FOR DELIVERY ACROSS THE BLOOD BRAIN BARRIER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025030099-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| US-20250011777-A1 | DELIVERY OF ANITSENSE OLIGOMERS BY MIRROR IMAGE PEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2025-01-09 | — | — | US | disclosed |
| US-12168059-B2 | Trimeric peptides for antisense delivery | SAREPTA THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240318179-A1 | MORPHOLINO OLIGOMERS FOR TREATMENT OF PERIPHERAL MYELIN PROTEIN 22 RELATED DISEASES | SAREPTA THERAPEUTICS, INC. | 2024-09-26 | — | — | US | disclosed |
| EP-4387676-A2 | DELIVERY OF ANITSENSE OLIGOMERS BY MIRROR IMAGE PEPTIDES | Sarepta Therapeutics, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20230020297-A1 | UOX-ALBUMIN CONJUGATE WITH CERTAIN NUMBERS OF ALBUMIN CONJUGATED THERETO, AND MANUFACTURING METHOD THEREOF | PROABTECH CO., LTD. (KR) | 2023-01-19 | — | — | US | disclosed |
| EP-3936501-A1 | SITE-SPECIFIC ANTIBODY CONJUGATION AND ANTIBODY-DRUG CONJUGATE AS SPECIFIC EXAMPLE THEREOF | ABTIS Co., Ltd. (KR) | 2022-01-12 | — | — | EP | disclosed |
| EP-3157571-B1 | FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS AG (CH) | 2021-11-24 | — | — | EP | disclosed |
| US-20210290772-A1 | TRIMERIC PEPTIDES FOR ANTISENSE DELIVERY | SAREPTA THERAPEUTICS, INC. | 2021-09-23 | — | — | US | disclosed |
| WO-2021150867-A1 | DESIGNING ANTISENSE OLIGONUCLEOTIDE DELIVERY PEPTIDES BY INTERPRETABLE MACHINE LEARNING | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
| EP-3829597-A1 | TRIMERIC PEPTIDES FOR ANTISENSE DELIVERY | Sarepta Therapeutics, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| WO-2021067458-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2021-04-08 | — | — | WO | disclosed |
| WO-2020028254-A1 | TRIMERIC PEPTIDES FOR ANTISENSE DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2020-02-06 | — | — | WO | disclosed |
| EP-3082877-B1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2019-08-28 | — | — | EP | disclosed |
| EP-3377112-A1 | CHEMICALLY-LOCKED BISPECIFIC ANTIBODIES | Sorrento Therapeutics, Inc. (US) | 2018-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168059-B2 | Trimeric peptides for antisense delivery | MTPN, MYOF, IAPP | CA12 2137/4885CA9 3231/4885ALOX15 4136/4885 |
| US-20250011777-A1 | DELIVERY OF ANITSENSE OLIGOMERS BY MIRROR IMAGE PEPTIDES | MYOF, IAPP, MTPN | CA12 2588/4885CA9 4084/4885ALOX15 3698/4885 |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | MYOF, TNNC1, MTPN | CA12 3111/4885CA9 3474/4885ALOX15 2687/4885 |
| US-20230020297-A1 | UOX-ALBUMIN CONJUGATE WITH CERTAIN NUMBERS OF ALBUMIN CONJUGATED THERETO, AND MANUFACTURING METHOD THEREOF | DAO, ALB, DDO | CA12 2918/4885CA9 2342/4885ALOX15 74/4885 |
| US-20210290772-A1 | TRIMERIC PEPTIDES FOR ANTISENSE DELIVERY | MTPN, MYOF, IAPP | CA12 2137/4885CA9 3231/4885ALOX15 4136/4885 |
| US-20250161469-A1 | TRIMERIC PEPTIDES FOR ANTISENSE DELIVERY | MTPN, MYOF, IAPP | CA12 2137/4885CA9 3240/4885ALOX15 4120/4885 |
| US-20250228954-A1 | Designing Antisense Oligonucleotide Delivery Peptides by Interpretable Machine Learning | MTPN, TNNC1, MYOF | CA12 2624/4885CA9 3486/4885ALOX15 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.